In an exploratory 100-participant study with Hokkaido University Hospital, one participant with a high-risk miSignal Scan result went on to imaging and surgery that removed adenocarcinoma in situ. A diagnosis rate for the study has not been reported, and the work has not been published in a peer-reviewed journal.
TOKYO, October 14, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, presented results from a prospective observational study run with Professor Tatsuya Kato of Hokkaido University Hospital and colleagues at IASLC WCLC 2025, the World Conference on Lung Cancer of the International Association for the Study of Lung Cancer, held in Barcelona, Spain, from September 6 to 9, 2025.
The study, titled "Evaluation of the Utility of miSignal for Lung Cancer Screening in the Hokkaido Region," was accepted as a general abstract.
The study gave 100 residents of Iwanai and Yoichi in Hokkaido a miSignal Scan urine test at no charge and followed up the participants whose results came back high risk. In that follow-up, one participant went on to diagnostic imaging, which found a lung lesion suspected of being cancer. That participant had surgery; the lesion was removed, and the outcome was described as a complete cure of Stage 0 lung cancer, specifically adenocarcinoma in situ.
Craif views the WCLC presentation as a step toward international recognition of miSignal. miSignal is offered in Japan as a risk assessment test and is not a medical device there. This release makes no claim regarding regulatory status in the United States.
What the Study Did
Craif provided 100 sets of miSignal Scan, a urine based cancer risk assessment test that combines microRNA analysis with AI, at no charge to people considered at high risk of lung cancer. Participants whose results came back high risk were followed up, and the study was designed to evaluate the rate at which lung cancer was diagnosed in that group. Craif and the Hokkaido University Hospital team also intend to follow participants over several years to estimate lung cancer incidence, its effect on prognosis, and the factors related to both.
What the Study Reported
One participant whose miSignal Scan result was high risk underwent diagnostic imaging, which found a lung lesion suspected of being cancer. Surgery removed the lesion. The result was described as removal of Stage 0 lung cancer, adenocarcinoma in situ, and a complete cure.
A diagnosis rate, sensitivity, specificity or other performance figure from this study has not been reported, and the work has not been published in a peer-reviewed journal. A single case does not establish how well the test performs.
The work was presented earlier, in May 2025, at the 42nd Annual Meeting of the Japanese Association for Chest Surgery.
Study Details
- Purpose: lung cancer surveillance using miSignal Scan in a group at high risk of lung cancer, evaluation of the rate at which lung cancer is diagnosed, and estimation of incidence, the effect on prognosis, and the factors related to both through follow up
- Study type: exploratory prospective observational study
- Participants: 100 residents of Iwanai and Yoichi, Hokkaido
- Period: through March 2025
- Investigators: Professor Tatsuya Kato, Hokkaido University Hospital, and colleagues, with Craif
- Presented as: a general abstract at IASLC WCLC 2025
About IASLC WCLC 2025
WCLC is the annual conference of the International Association for the Study of Lung Cancer. It brings together clinicians, researchers and pharmaceutical industry participants from around the world. Data tied to clinical trials and to treatment guidelines are presented there, and the meeting influences clinical practice internationally. Beyond the science, the meeting also contributes to public health work such as tobacco control policy and the promotion of early diagnosis. Craif regards it as the most authoritative international conference in lung cancer.
- Dates: September 6 to 9, 2025
- Location: Barcelona, Spain
- Organizer: International Association for the Study of Lung Cancer
- Website: https://wclc.iaslc.org/
About the miSignal Series
The miSignal series is a set of cancer risk assessment tests intended to support prevention and early detection. miSignal Scan assesses cancer risk using microRNA analysis and AI. miSignal Lite is a simpler risk test. miSignal Navi is a genetic test focused on cancer. miSignal Check monitors DNA damage. All of them use only a urine or saliva sample, so there is no physical burden on the person tested. More information: https://misignal.jp/
The miSignal series products are not medical devices. They determine risk by statistical calculation from the information analyzed. They are not a medical diagnosis of the presence or absence of cancer and they cannot substitute for diagnosis by a physician. A result assessed as low risk does not mean that cancer is absent or that cancer will not develop in future.
About Craif
Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.
